8 Topamax Alternatives for Chronic Migraine

Topiramate, sold under the brand name Topamax, has been a go-to preventive medication for migraine for over two decades. It works, but for many people living with chronic migraine, the side effects make it hard to stay on. Cognitive fog, tingling in the hands and feet, weight changes, and mood shifts lead a significant number of patients to stop treatment before it has a chance to help.

If you are exploring options beyond topiramate, the good news is that the treatment landscape for chronic migraine has expanded considerably. Behavioral therapies, newer medications with fewer side effects, lifestyle interventions, and FDA-cleared devices all offer paths worth discussing with your healthcare provider. This article covers eight evidence-based alternatives, starting with behavioral approaches that target the neurological patterns behind chronic migraine.

Key Takeaways

• Topiramate is effective for migraine prevention, but high side-effect rates including paresthesia and cognitive symptoms lead many patients to discontinue treatment.
• The ACP's 2025 guideline ranks topiramate third-line for episodic migraine prevention, behind beta-blockers, SNRIs, and CGRP-targeting therapies.
• Behavioral approaches like CBT and mindfulness may reduce migraine frequency in adults and can be used alongside or instead of medications.
• CGRP monoclonal antibodies are now positioned as first-line preventive options by the American Headache Society, with better tolerability profiles than topiramate.
• Lin Health's approach is based on behavioral and neuroplastic pain research, delivering coach-led behavioral support covered by insurance in most major states.

Why People Look for Topamax Alternatives

Chronic migraine, 15+ headache days monthly for longer than three months with at least 8 days meeting full migraine criteria, affects roughly 0.9% of US adults. That translates to nearly 3 million people navigating a condition that disrupts work, relationships, and daily functioning.

Topiramate remains one of the most-prescribed oral preventives for migraine. A 2023 meta-analysis from the European Headache Federation confirmed it reduces monthly migraine days compared to placebo, with a number needed to treat of 6. However, the same analysis found that topiramate carries a number needed to harm of just 3 for paresthesia (tingling or numbness), 14 for taste disturbances, and 25 for memory problems. Across trials, 80 more per 1,000 discontinued due to adverse events compared to placebo.

Beyond tolerability, topiramate carries reproductive safety concerns. The FDA classifies it as pregnancy category D, citing increased risk of oral clefts and small-for-gestational-age newborns when used during pregnancy. For people of childbearing age, this risk often makes topiramate a nonstarter.

These factors help explain why the ACP's 2025 clinical guideline placed topiramate third-line for episodic migraine prevention, recommending it only after trials of beta-blockers, amitriptyline, venlafaxine, and CGRP-targeting therapies have been attempted. The guideline also notes that compared to CGRP monoclonal antibodies, topiramate is linked to higher frequency of migraine days and greater acute medication use.

1. Cognitive Behavioral Therapy (CBT) for Migraine

What it is

CBT is a structured form of talk therapy that helps identify and change thought patterns and behaviors contributing to pain. In the context of chronic migraine, CBT targets the fear-avoidance cycle, catastrophizing about attacks, and stress responses that can amplify migraine frequency and severity.

What the evidence shows

A 2025 systematic review and meta-analysis evaluating 50 adult trials and over 6,000 participants found that CBT may reduce migraine frequency in adults, with relaxation training showing similar effects. The strength of evidence is rated low, meaning results are promising but further high-quality trials are needed.

CBT's advantages over topiramate include zero pharmacological side effects, compatibility with pregnancy, and the ability to build long-term self-management skills. Where topiramate suppresses neural excitability through medication, CBT retrains pain-signal processing, targeting the behavioral and emotional drivers that perpetuate chronic migraine cycles.

Who it may help

CBT may be particularly worth exploring for people who:

• Cannot tolerate medication side effects
• Are pregnant, planning pregnancy, or breastfeeding
• Want to reduce reliance on acute medications (which can contribute to medication-overuse headache)
• Experience significant anxiety or catastrophizing around migraine attacks

2. Mindfulness-Based Stress Reduction (MBSR)

What it is

MBSR is a structured 8-week program combining meditation, body awareness, and gentle movement. For chronic migraine, it specifically addresses the stress-pain feedback loop, where anticipating attacks creates physiological arousal that can trigger more attacks.

What the evidence shows

A randomized clinical trial published in JAMA Internal Medicine compared MBSR to headache education in adults with 4 to 20 migraine days per month. MBSR improved disability and coping outcomes including quality of life, self-efficacy, and pain catastrophizing through 36 weeks of follow-up. The primary outcome of migraine frequency did not differ significantly between groups, but the broad improvements in how participants experienced and coped with migraine attacks were clinically meaningful.

Like CBT, mindfulness carries no medication-related side effects. A 2025 systematic review confirmed that mindfulness-based therapies are among the supported behavioral interventions for migraine prevention, though the certainty remains low.

Who it may help

MBSR may be a good fit for people whose migraines are closely linked to stress, those who notice that anxiety about the next attack makes symptoms worse, or anyone looking for a drug-free migraine approach.

3. CGRP Monoclonal Antibodies

What they are

Calcitonin gene-related peptide (CGRP) monoclonal antibodies are injectable medications designed to block the CGRP pathway, a key driver of migraine pain. Four are currently available: erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti).

What the evidence shows

The American Headache Society's 2024 position statement removed prior-failure requirements for CGRP-targeting therapies, positioning them as first-line options for migraine prevention. This represents a significant shift from the previous approach that required patients to fail older preventives before accessing these newer treatments.

A Bayesian network meta-analysis focused specifically on chronic migraine found that all four monoclonal antibodies reduce monthly migraine days, with 50% responder rates ranging from approximately 42% to 59%. Real-world data suggest these rates improve over time, reaching above 60% at 12 months.

In head-to-head comparisons, erenumab showed higher responder rates than topiramate (55.4% versus 31.2%), with a discontinuation rate of 10.6% compared to topiramate's 38.9%.

Who they may help

CGRP monoclonal antibodies are appropriate for adults with chronic or episodic migraine who want an effective preventive with fewer cognitive side effects than topiramate. Common side effects are generally mild, including injection site reactions and constipation.

Important: The ACP's 2025 guideline and the AHS's 2024 position statement disagree on where CGRP therapies belong in the treatment sequence. The AHS recommends them as first-line, while the ACP places them as second-line after older, less expensive oral preventives. Discuss both perspectives with your provider.

4. Oral CGRP Antagonists (Gepants)

What they are

Gepants are small-molecule CGRP receptor antagonists taken as daily oral tablets, offering an alternative to the injectable monoclonal antibodies. Atogepant (Qulipta) is the first and currently only oral CGRP antagonist approved for chronic migraine prevention in adults, at a dose of 60 mg daily. Rimegepant (Nurtec ODT) is approved for episodic migraine prevention.

What the evidence shows

In the phase 3 PROGRESS trial, atogepant met its primary endpoint for reducing monthly migraine days in adults with chronic migraine, along with all six key secondary endpoints. Because gepants target the same CGRP pathway as the monoclonal antibodies but in oral form, they provide a needle-free option for people who prefer not to use injections.

Who they may help

Gepants may suit people who want the CGRP mechanism of action without injections, those who have difficulty with self-administered injections, or people whose insurance covers oral medications more favorably.

5. OnabotulinumtoxinA (Botox)

What it is

OnabotulinumtoxinA, marketed as Botox, involves injections at 31 specific head and neck sites every 12 weeks. It is the only botulinum toxin approved for chronic migraine prevention, not episodic migraine.

What the evidence shows

The pooled PREEMPT trial data showed Botox reduces monthly headache days compared to placebo in adults with chronic migraine. Adverse events occurred in 28.5% of the Botox group versus 12.4% with placebo, with neck pain (9%) and injection site pain (9%) among the most common.

Compared to topiramate, Botox has higher completion rates and lower adverse event frequency. One comparative study found 81% of Botox patients completed treatment versus 59% for topiramate, with adverse events in 17% versus 70%.

Who it may help

Botox is specifically indicated for people who meet the chronic migraine threshold of 15 or more headache days per month. It requires in-office visits every 12 weeks, which can be a barrier for some but an advantage for people who prefer not to manage daily medications.

6. Aerobic Exercise

What it is

Regular aerobic exercise, including walking, swimming, cycling, and jogging, appears to influence migraine through multiple pathways: reducing stress hormones, improving sleep quality, and modulating pain-processing circuits in the brain.

What the evidence shows

A 2026 dose-response meta-analysis found that aerobic exercise reduces pain and frequency in adults with migraine. The researchers identified a preliminary minimum effective dose of approximately 3 sessions of 30 minutes per week, though they noted this recommendation needs confirmation in future trials. A companion network meta-analysis found that combined aerobic-strength training produced the strongest effects.

Who it may help

Exercise is broadly accessible, free, and carries additional cardiovascular and mental health benefits. It works well as a complement to other approaches rather than as a standalone replacement, particularly for people with high-frequency chronic migraine.

7. Nutraceutical Supplements

What they are

Three supplements have the most research support for migraine prevention: magnesium (400-500 mg/day), riboflavin or vitamin B2 (400 mg/day), and coenzyme Q10. These are widely available over the counter and are generally well tolerated.

What the evidence shows

The National Center for Complementary and Integrative Health notes there is limited migraine-prevention evidence for magnesium, riboflavin, and CoQ10, while emphasizing that additional rigorous research is needed. Magnesium in particular has been rated "probably effective" by the American Migraine Foundation, though the underlying formal guideline grades are no longer considered current.

Who they may help

Supplements may be worth discussing with your clinician as a low-risk addition to a broader migraine management plan. They are not a substitute for established preventive treatments but can complement behavioral, lifestyle, and medical approaches. High-dose magnesium can cause gastrointestinal side effects, and all supplements should be discussed with a healthcare provider before starting.

8. Neuromodulation Devices

What they are

FDA-cleared neuromodulation devices deliver electrical or magnetic stimulation to specific nerve pathways involved in migraine. Three devices have weak preventive recommendations from the International Headache Society: Cefaly (external trigeminal nerve stimulation), Nerivio (remote electrical neuromodulation), and gammaCore (non-invasive vagus nerve stimulation).

What the evidence shows

The IHS's 2024/2025 evidence-based guidelines issued conditional recommendations for these three devices for migraine prevention, noting that evidence quality ranges from very low to moderate. The recommendations are characterized as "weak," meaning they may be appropriate for some patients but should not be considered first-line for everyone. These devices are drug-free and carry minimal side effects, though they require a prescription and ongoing costs for replacement electrodes or app subscriptions.

Who they may help

Neuromodulation devices may suit people who want to avoid all medications, those who have not responded to multiple drug classes, or people looking for an added complementary tool alongside behavioral and medical treatments.

How Lin Health Helps with Chronic Migraine

The alternatives in this article fall into two broad categories: treatments that suppress symptoms (medications, injections, devices) and approaches that retrain how the brain processes pain signals (behavioral therapies, lifestyle changes). Lin Health's program focuses on the second category.

Chronic migraine often involves a cycle where the brain's pain alarm becomes stuck in a heightened state. Anticipating attacks creates stress, which triggers physiological arousal, which lowers the threshold for the next migraine. Fear of movement, emotional responses to pain, and catastrophizing thought patterns reinforce this loop. Lin Health's approach is based on neuroplastic research that targets these behavioral and neurological patterns directly.

What the program looks like:

• Coach-led sessions: Weekly calls with a trained recovery coach who guides you through evidence-based behavioral techniques including CBT, mindfulness, acceptance and commitment therapy, and somatic tracking
• App-based learning: Between sessions, the Lin Health app provides structured modules and practice exercises designed by clinical experts
• Insurance covered: Lin Health is covered by most major insurance plans in Colorado, Texas, Florida, California, and New York, with most patients paying zero out of pocket
• Short wait times: Same-day callback to check eligibility, with program enrollment typically within days

Unlike self-guided apps or books, Lin Health pairs you with a dedicated coach who specializes in persistent symptom conditions including chronic migraine. Unlike general therapists who may not have training in pain neuroscience, Lin Health coaches are specifically trained to work with the behavioral and emotional drivers of chronic pain and migraine.

Behavioral approaches work well as part of a coordinated plan with your neurologist or primary care provider, not as a replacement for medical oversight. If topiramate's side effects have you looking for a different path, a behavioral approach may be worth exploring alongside your current treatment.

Lin Health offers behavioral and lifestyle support for chronic migraine, delivered by trained recovery coaches and covered by most insurance plans in CO, TX, FL, CA, and NY. Wait times are short, often a same-day call. Check your eligibility.

FAQ

What is chronic migraine, and how is it different from regular migraine?

Chronic migraine means having headaches on 15 or more days per month for longer than three months, with at least 8 of those days meeting full migraine criteria. Episodic migraine involves fewer than 15 headache days per month. The distinction matters because some treatments, like Botox, are approved only for chronic migraine.

Can I stop taking Topamax and switch to a behavioral approach instead?

Do not stop or change a medication without talking to your prescribing provider first. Behavioral approaches like CBT and mindfulness can be started alongside existing medications. Your provider may adjust your treatment plan over time based on your response.

Are behavioral therapies covered by insurance for migraine?

Coverage varies. Lin Health's coach-led behavioral program is covered by most major insurance plans in several states, with most enrolled patients paying nothing out of pocket. Traditional CBT with a licensed therapist may also be covered, though wait times and out-of-pocket costs tend to be higher.

How long does it take for alternatives to Topamax to start working?

It depends on the approach. CGRP monoclonal antibodies may show benefits within the first month. Behavioral therapies like CBT typically require 8 to 12 weeks of consistent practice before frequency reductions become noticeable. Botox often requires two to three treatment cycles (6 to 9 months). Your provider can help set realistic expectations.

Can I use behavioral therapy alongside Botox or CGRP medications?

Yes. Behavioral approaches complement medical treatments. Combining a CGRP monoclonal antibody or Botox with CBT-based techniques addresses both the biological and behavioral aspects of chronic migraine, and several headache specialists recommend this layered approach.

Is Topamax still a good option for anyone?

Topiramate remains effective for some people who tolerate it well. If you have been on topiramate without significant side effects and your migraine frequency has improved, there may be no reason to switch. The alternatives in this article are most relevant for people experiencing side effects, those who have not responded adequately, or those with contraindications like pregnancy.

This article is for informational purposes only and is not medical advice. It does not replace the guidance of a qualified healthcare provider. Consult your neurologist or primary care physician before making changes to your migraine treatment plan.

Last reviewed: July 2026